Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Havrix Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

NCT05084508
View directory record Official record
Conditions
Chickenpox
Interventions
Investigational varicella vaccine low potency, Investigational varicella vaccine medium potency, Investigational varicella vaccine high potency, Licensed varicella vaccine Lot 1, Licensed varicella vaccine Lot 2, Measles, mumps, and rubella vaccine, Hepatitis A vaccine, 13-valent pneumococcal conjugate vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
41
States / cities
Bryant, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 17, 2026, 9:54 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant With Post-transplant Cyclophosphamide

NCT01282216
View directory record Official record
Conditions
Transplant-Related Cancer
Interventions
Havrix, PCV13
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Oct 17, 2026, 9:54 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Trial of Antibody Responses by Vitamin Supplementation

NCT03859687
View directory record Official record
Conditions
Healthy Participants
Interventions
Vitamin A supplementation, No vitamin A supplementation
Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 4 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 17, 2026, 9:54 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children

NCT00197015
View directory record Official record
Conditions
Hepatitis A
Interventions
Havrix®, M-M-R®II, VARIVAX®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 13 Months
Enrollment
1,474 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
42
States / cities
Cabot, Arkansas • Jonesboro, Arkansas • North Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 17, 2026, 9:54 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old

NCT00224484
View directory record Official record
Conditions
Herpes Simplex
Interventions
GSK208141, Havrix (investigational formulation), Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 17 Years · Female only
Enrollment
5,960 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
66
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 17, 2026, 9:54 PM EDT
Terminated Phase 4 Interventional

The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)

NCT05543642
View directory record Official record
Conditions
Rheumatic Diseases
Interventions
Hepatitis A vaccine, Diphtheria, pertussis, and tetanus booster vaccine
Biological
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Northport, Alabama • Riverview, Florida • Boise, Idaho + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 17, 2026, 9:54 PM EDT
Completed No phase listed Observational

Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors

NCT02747407
View directory record Official record
Conditions
Astrocytoma, Glioma, Oligodendroglioma
Interventions
Hepatitis A Vaccine, Laboratory Biomarker Analysis, Tetanus Toxoid Vaccine, Trivalent Influenza Vaccine
Biological · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 17, 2026, 9:54 PM EDT
Completed Phase 3 Interventional Results available

Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects

NCT00937950
View directory record Official record
Conditions
Infections, Papillomavirus
Interventions
Gynaecological follow-up
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
2,022 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
18
States / cities
Clearwater, Florida • Miami, Florida • Honolulu, Hawaii + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 17, 2026, 9:54 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

NCT03537508
View directory record Official record
Conditions
Healthy Volunteers (Meningococcal Infection)
Interventions
MenACYW conjugate vaccine, MenACYW-135 conjugate vaccine, DTaP-IPV//Hib vaccine, Pneumococcal 13-valent conjugate vaccine, Pentavalent rotavirus vaccine, Hepatitis B vaccine, Measles, mumps, rubella (MMR) vaccine, Varicella vaccine, Hepatitis A vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 89 Days
Enrollment
2,627 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
65
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 17, 2026, 9:54 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

NCT06824194
View directory record Official record
Conditions
Pneumococcal Immunization
Interventions
PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, Rotarix, RotaTeq, Vaxelis vaccine, Varivax, Priorix, VAQTA, Havrix
Biological
Lead sponsor
Sanofi
Industry
Eligibility
42 Days to 89 Days
Enrollment
2,360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
103
States / cities
Birmingham, Alabama • Guntersville, Alabama • Oneonta, Alabama + 81 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 17, 2026, 9:54 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants

NCT00474526
View directory record Official record
Conditions
Meningitis, Meningococcal
Interventions
Meningococcal ACWY Conjugate Vaccine, DTaP-IPV-HBV, Hib, Rotavirus, Pneumococcal 7-valent Conjugate Vaccine, HAV, MMR-V, DTaP
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
2 Months to 2 Months
Enrollment
4,545 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
53
States / cities
Bessemer, Alabama • Birmingham, Alabama • Downey, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2014 · Synced Oct 17, 2026, 9:54 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents

NCT02212457
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Bexsero, Saline Placebo, Havrix, MenABCWY
Biological · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 18 Years
Enrollment
1,063 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
13
States / cities
Jonesboro, Arkansas • Hialeah, Florida • Melbourne, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 17, 2026, 9:54 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age

NCT00578175
View directory record Official record
Conditions
Varicella, Rubella, Mumps, Measles
Interventions
Priorix-Tetra™ (MMRV vaccine 208136), ProQuad®, Havrix®, Prevnar®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 14 Months
Enrollment
1,851 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
141
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 17, 2026, 9:54 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

NCT02184572
View directory record Official record
Conditions
Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine
Interventions
Priorix, M-M-R II, Varivax, Havrix, Prevnar 13
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
1,742 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
80
States / cities
Birmingham, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 69 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 17, 2026, 9:54 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

NCT01681992
View directory record Official record
Conditions
Measles, Mumps, Rubella, Measles-Mumps-Rubella Vaccine
Interventions
Priorix, M-M-R II, Varivax, Havrix, Prevnar 13
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
4,538 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 17, 2026, 9:54 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age

NCT00197002
View directory record Official record
Conditions
Hepatitis A
Interventions
GSK Biologicals 2-dose inactivated hepatitis A vaccine (Havrix), Prevnar™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 13 Months
Enrollment
521 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
18
States / cities
Centennial, Colorado • Bardstown, Kentucky • Louisville, Kentucky + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 17, 2026, 9:54 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age

NCT01978093
View directory record Official record
Conditions
Neisseria Meningitidis, Haemophilus Influenzae Type b
Interventions
Hib-MenCY-TT (MenHibrix®), Pediarix®, Rotarix®, Prevnar 13®, PedvaxHIB®, Havrix®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
26
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 17, 2026, 9:54 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

NCT06824181
View directory record Official record
Conditions
Pneumococcal Immunization
Interventions
PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, Rotarix, RotaTeq, Vaxelis vaccine, Varivax, Priorix, VAQTA, Havrix
Biological
Lead sponsor
Sanofi
Industry
Eligibility
42 Days to 89 Days
Enrollment
580 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
17
States / cities
Los Angeles, California • Hollywood, Florida • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 17, 2026, 9:54 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age

NCT01702428
View directory record Official record
Conditions
Rubella, Measles, Mumps
Interventions
Priorix, M-M-R II, Varivax, Havrix, Prevnar 13
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
5,016 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
62
States / cities
Dothan, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 17, 2026, 9:54 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months

NCT00197236
View directory record Official record
Conditions
Hepatitis A
Interventions
Havrix™, Infanrix™, ActHIB™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 13 Months
Enrollment
468 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
22
States / cities
Phoenix, Arizona • Oakland, California • San Ramon, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 17, 2026, 9:54 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18

NCT00122681
View directory record Official record
Conditions
Infections, Papillomavirus
Interventions
Cervarix™, Havrix™-based investigational formulation
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years to 25 Years · Female only
Enrollment
18,729 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
50
States / cities
Birmingham, Alabama • Fountain Valley, California • San Diego, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 17, 2026, 9:54 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age

NCT00861744
View directory record Official record
Conditions
Rubella, Mumps, Measles, Measles-Mumps-Rubella Vaccine
Interventions
GSK Biological's investigational vaccine 209762, M-M-R® II (Merck and Co), Varivax®, Havrix®, Prevnar®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
1,259 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
45
States / cities
Tuscaloosa, Alabama • Conway, Arkansas • Jonesboro, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Oct 17, 2026, 9:54 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

NCT01352793
View directory record Official record
Conditions
Meningitis, Meningococcal
Interventions
rLP2086 vaccine, control
Biological
Lead sponsor
Pfizer
Industry
Eligibility
10 Years to 25 Years
Enrollment
5,715 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
39
States / cities
Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Oct 17, 2026, 9:54 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years

NCT01830855
View directory record Official record
Conditions
Meningococcal Vaccine
Interventions
rLP2086, Havrix (HAV), Saline
Biological
Lead sponsor
Pfizer
Industry
Eligibility
10 Years to 18 Years
Enrollment
3,596 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
62
States / cities
Birmingham, Alabama • Dothan, Alabama • Harrisburg, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2016 · Synced Oct 17, 2026, 9:54 PM EDT